{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:28:05Z","timestamp":1782170885141,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Semaglutide is a glucagon\u2010like\u2010peptide\u20101 (GLP\u20101) analogue marketed for once\u2010weekly subcutaneous administration for type 2 diabetes mellitus. Like other long\u2010acting GLP\u20101 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of absorption of orally co\u2010administered drugs. The objective of the current analysis was to evaluate the effects on the gastric emptying rate caused by semaglutide on pharmacokinetic model parameters of paracetamol and atorvastatin in healthy subjects. Non\u2010linear mixed effect modeling was used to estimate population pharmacokinetic model parameters of paracetamol and atorvastatin after single doses with or without semaglutide. The absorption rate (ka) of paracetamol decreased by 53% when co\u2010administered with semaglutide. For atorvastatin, ka and transit compartment rate (ktr) decreased by 72% and 91%, respectively. Thus, gastric emptying, measured as T50, i.e., drug disappearance from the absorption compartments, showed an additional 5\u2010min delay for paracetamol and a 67\u2010min delay for atorvastatin when co\u2010administered with semaglutide. Semaglutide affected pharmacokinetic model parameters of paracetamol and atorvastatin, and minor quantitative differences in gastric emptying between placebo vs. semaglutide administration were observed. However, these effects of semaglutide were considered not to be of clinical relevance.<\/jats:p><\/jats:sec>","DOI":"10.1002\/prp2.962","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:55:45Z","timestamp":1657259745000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population pharmacokinetic of paracetamol and atorvastatin with co\u2010administration of semaglutide"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-7151","authenticated-orcid":false,"given":"Emilie K.","family":"Langeskov","sequence":"first","affiliation":[{"name":"Department of Drug Design and Pharmacology University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-8023","authenticated-orcid":false,"given":"Kim","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Discovery &amp; Development PKPD Novo Nordisk A\/S  M\u00e5l\u00f8v Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001"},{"issue":"5","key":"e_1_2_11_3_1","first-page":"69","article-title":"The treatment of type 2 diabetes","volume":"111","author":"Pfeiffer AF","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0532-6"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296800"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01316798"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118411"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13120"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz047"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2006.02.002"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1367-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2008.30.10.1316828"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.07.017"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2001.00249.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136618"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3844-9"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(88)80022-6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00278"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12447"},{"key":"e_1_2_11_22_1","unstructured":"European Agency for the Evaluation of Medicinal Products.International Conference on Harmonisation\u2010World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Harmonised Tripartite Guideline. Good Clinical Practice 2017. Accessed September 17 2021.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e\u20106\u2010r2\u2010guideline\u2010good\u2010clinical\u2010practice\u2010step\u20105_en.pdf"},{"key":"e_1_2_11_23_1","unstructured":"World Medical Association.Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly Edinburgh Scotland October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General assembly Tokyo 2004. Accessed September 17 2021.https:\/\/www.wma.net\/wp\u2010content\/uploads\/2016\/11\/DoH\u2010Oct2013\u2010JAMA.pdf"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12161"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"issue":"1","key":"e_1_2_11_26_1","first-page":"S313","article-title":"The concise guide to pharmacology 2021\/22: enzymes","volume":"178","author":"Alexander SP","year":"2021","journal-title":"Br J Pharmacol"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"issue":"5","key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"595\u2010604.","DOI":"10.1002\/jcph.1555","article-title":"Population pharmacokinetic modeling of acetaminophen protein adducts in adults and children","volume":"60","author":"Jiang S","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13770"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0531-7"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14110"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.549"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535980-000000000-00000"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717540802481380"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.08.060"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767001-00007"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T14:40:25Z","timestamp":1692801625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/prp2.962"],"URL":"https:\/\/doi.org\/10.1002\/prp2.962","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"2021-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00962"}}